Chronic Pancreatitis Clinical Research Consortium (CPCRC) Data Coordinating Center (CPCRC-DCC)

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Linked publications, trials & patents

Abstract

Project Summary Research in the treatment for diseases of the exocrine pancreas, including chronic pancreatitis (CP), pancreatogenic diabetes mellitus (DM), and pancreatic ductal adenocarcinoma (PDAC), has been hampered by disease heterogeneity, the lack of systematically collected clinical outcome measures in longitudinal studies linked with biospecimens, and slow pace in biomarker and therapeutic development. Given the increasing incidence and prevalence of CP and its association to PDAC, its complications, high mortality rate, and associated healthcare cost, the NIH established in 2015 a consortium for the study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer as multidisciplinary teams to undertake a comprehensive clinical, epidemiological, and biological characterization of patients with CP (including recurrent acute pancreatitis) to develop treatments and biomarker tests, and gain insight into the pathophysiology of CP and its sequela: chronic pain, pancreatic exocrine and endocrine insufficiency, diabetes and pancreatic cancer association. In the last nine years, the Coordination and Data Management Center (Center) of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (Consortium) has provided critical administrative, regulatory, managerial, logistic, analytic, and financial functions for the consortium, enabling the successful launch of four multicenter studies (i.e., PROCEED, INSPPIRE 2, NOD, DETECT) that aim to understand the relationship between CP, DM, and PDAC, and to better define and characterize Type 3c diabetes. In the next five years, the consortium will be renamed the Chronic Pancreatitis Clinical Research Consortium (CPCRC), and the Center will be renamed the Data Coordinating Center (DCC) to reflect the revised research focus on CP, both in children and adults and to pursue and expand the objectives of the former consortium in these areas. The DCC will further refine, optimize and innovate its time-tested infrastructure, operation procedures, and organizational structure to provide strong and continued support for the CPCRC’s studies. Specifically, we aim to (1) provide operation and coordination support; (2) continue the accrual and follow-up for the two ongoing longitudinal cohort studies, PROCEED and INSPPIRE 2; (3) support the infrastructure for biomarker development and therapeutic trials, and manage the CPCRC biobank to process, safeguard and distribute the study biospecimens for the conduct of studies approved by the CPCRC; and (4) design and support new studies selected by the CPCRC.